Laser zaps brain tumor, then chemo moves in: new combo trial opens
NCT ID NCT07145112
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a two-step approach for glioblastoma that has come back after standard treatment. First, doctors use a laser guided by MRI to heat and destroy part of the tumor. Then, within a week, patients take the chemotherapy drug lomustine. The study will enroll 20 adults to see if the combination is safe and doable, and will track survival for up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lomustine (CCNU) chemotherapy
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma that combines heat-based tumor destruction with chemotherapy.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so safety and feasibility are the main goals. The combination may cause serious side effects or not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95827, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact